shutterstock_1080864311_sruilk
sruilk / Shutterstock.com
10 May 2019Big Pharma

Novartis to boost eye care portfolio with $3.4bn buy

Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from  Takeda.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
25 November 2019   Swiss drug company Novartis has agreed to buy The Medicines Co for $9.7 billion, as it focuses on expanding its cardiovascular portfolio.

More on this story

Big Pharma
25 November 2019   Swiss drug company Novartis has agreed to buy The Medicines Co for $9.7 billion, as it focuses on expanding its cardiovascular portfolio.

More on this story

Big Pharma
25 November 2019   Swiss drug company Novartis has agreed to buy The Medicines Co for $9.7 billion, as it focuses on expanding its cardiovascular portfolio.